Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China
BackgroundAs a new non-factor therapy for hemophilia A (HA), real-world study of emicizumab is still scarce. This study aimed to investigate the real-world use of emicizumab in Chinese boys with HA.MethodsPatients with moderate or severe HA were enrolled at Beijing Children's Hospital. They take emi...
Furkejuvvon:
| Váldodahkkit: | , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Frontiers Media S.A.
2022-10-01
|
| Ráidu: | Frontiers in Pediatrics |
| Fáttát: | |
| Liŋkkat: | https://www.frontiersin.org/articles/10.3389/fped.2022.992267/full |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|